印明柱：国家级青年人才

编辑：王天怡 发布时间：2023-01-17 21:22


kaiyun开云官方网站附属三峡公司特聘教授，博士生导师

联系方式：yinmingzhu2008@126.com

教育经历：

2015.09-2018.06，耶鲁大学&中国药科大学联合培养 中西医结合基础专业（博士）；

2008.09-2011.06，哈尔滨医科大学 肿瘤学专业（硕士）；

2002.09-2008.06，哈尔滨医科大学 临床医学专业（俄语班）（本科）；

工作经历：

2022.11-至今，kaiyun开云官方网站附属三峡公司特聘教授，博士生导师，肿瘤早期诊断中心、分子病理中心、转化医学研究中心、临床研究中心主任；

2020.08-至今，美国耶鲁大学开云全站中国有限公司，病理科，兼职助理教授；

2020.12-2022.11，中南大学湘雅公司皮肤科副主任；

2018.03-2022.11，中南大学湘雅公司特聘教授、博士生导师，皮肤健康与疾病湖南省工程研究中心常务副主任；

2017.12-2018.03，美国耶鲁大学开云全站中国有限公司，病理科，副研究员；

2012.11-2017.12，美国耶鲁大学开云全站中国有限公司，病理科，博士后；

2011.11-2012.11，美国国立卫生研究院抗衰老研究所（NIH/NIA）遗传系博士后；

2014.08-2017.09，哈尔滨医科大学附属肿瘤公司，主治医师；

2011.07-2014.07, 哈尔滨医科大学附属肿瘤公司 临床医生（期间出国留学）。

获社会兼职：

2023年-2026年，中国抗癌协会肿瘤基因诊断专委会中线（NUT）癌基因诊断工作组组长；

2023年-2028年，中国食品药品企业质量安全促进会-细胞医药分会副会长；

2023年-2028年，重庆市医药生物技术协会肿瘤临床试验专业委员会副主任委员；

2022年-至今，中国旅美科技协会总会副会长兼重庆联络处主任；

2021年-2026年，湖南省口腔医学会首届口腔-头颈肿瘤MDT专业委员会常委；

2021年-2024年，中国微循环学会转化医学专委会常委、青年副主任委员；

2018年-2021年，中国医师协会皮肤科医师分会罕见病遗传病专委会委员；

2021年-至今，《Tumor Discovery》杂志创刊主编；

2020年-至今，《Cancer Translation Medicine》杂志副主编；

获得荣誉：

2023年，获中国发明协会发明创业创新一等奖；

2023年，获高等学校科学技术进步一等奖；

2022年，获湖南省留学人员创业启动支持计划项目一等奖（创意组）；

2018年，获黑龙江省人民政府科技进步二等奖；

发明专利：

1. 专利名称：宫颈癌患者使用紫杉醇和顺铂进行化疗敏感性预测方法。发明人：侯艳，印明柱，孙风宇，娄阁，李康。申请号：201510164414.2

2. 专利名称：杂环化合物及其盐、制备方法、用途和药物。发明人：印明柱，陈翔。专利号：ZL2018 1 1204859.9  授权号：CN109134448 B

3. 专利名称：荧光酶抑制剂筛选模型建立方法及荧光酶抑制剂筛选方法。发明人：印明柱、曹东升、杨梓宜、陈翔。申请号：202010715628.5

4. 专利名称：分子靶标蛋白的筛选方法、装置、计算机设备和存储介质。发明人：印明柱、曹东升、杨素青、陈翔。申请号：202010716290.5

5. 专利名称：胶体筛选模型的构建方法和胶体筛选方法。发明人：曹东升、印明柱、陈翔、杨梓宜。申请号：202010818121.2

6. 专利名称：药物与靶点间的相互作用关系预测方法及装置。发明人：曹东升、印明柱、陈翔、杨素青、程岩。申请号：202010824226.9

7. 专利名称：诱导肝毒性预测方法、装置、计算机设备及存储介质。发明人：曹东升、印明柱、陈翔、付丽、刘璐。申请号：202010835987.4

8. 专利名称：药物副作用关系预测方法、系统、计算机设备和存储介质。发明人：曹东升、印明柱、陈翔、杨素青。申请号：202010837504.4

9. 专利名称：细胞分类方法、装置、计算机设备和存储介质。发明人：印明柱、李轶群、陈翔。申请号：202010840988.8

10. 专利名称：原代肢端黑色素瘤细胞的培养方法及培养试剂盒。发明人：印明柱、胡睿、陈翔。专利号：ZL 2020 1 0705199.3 授权号：CN 113957052 B

11. PCT专利名称：CD147-ANTIBODIES AND ANTI-CD147-CAR-T CELLS。发明人：陈翔、印明柱。申请号：119995-8033.US00

12. 专利名称：一种人细胞外基质金属蛋白酶诱导因子磁微粒化学发光免疫定量检测试剂盒及其检测方法。发明人：印明柱、陈翔。申请号：202210207499.8

13. 专利名称：5-硫-D-葡萄糖的合成方法。发明人：廖潇啸、印明柱、陈翔。申请号：202210336519.1

14. 专利名称：一种同时识别多种恶性肿瘤细胞的核酸适体及其应用。发明人：蒲颖、印明柱、陈翔。专利号：ZL 2022 1 0207946.X  授权号：CN 114507668 B

课题基金：

序号

项目名称

主持/承担

立项编号

经费(万元)

起止年月

性质及来源

1

BRD4及其抑制剂调控HIPPO/YAP1通路防治黑素瘤增殖、侵袭及转移机制研究

主持

82073020

55

2021/01-2024/12

国家自然科学基金面上项目

2

基于BRD4通过c-MYC-MYH9轴调控MYH9与HIF-1α相互作用探讨BET抑制剂防治黑素瘤转移的机制研究

主持

81874138

57

2019/01-2022/12

国家自然科学基金面上项目

3

老年常见皮肤病防控及干预关键技术创新及应用

子课题负责人

2022YFC3601802

388.77

2023/01-2028/12

科技部重点研发项目

4

皮肤疾病药理学

81202282

2021JJ10073

50

2021/01-2023/12

湖南省杰出青年基金

成果转化:

新药等级

成果简介

本人作用和主要经济社会效益

 

 

 

1.1靶向新药

BET抑制剂以BRD2/3/4为靶标，主要通过其溴化结构域蛋白（BET）特异性地识别乙酰化赖氨酸的保守蛋白结构域，在转录蛋白表达中通过参与蛋白-蛋白的相互作用，促进蛋白复合物形成并提高部分基因的转录功能。临床试验观察显示：BET抑制剂对血液肿瘤治疗表现尚好，但是对实体瘤治疗有相当大的局限性，成为本领域的技术瓶颈。现阶段团队已开发的具有独立知识产权的1.1类新药BET抑制剂NHWD-870，具有高效及高特异性特点，该项目已获批国家药监局临床试验批件2项，正在进行临床Ⅰ期试验。

申请人作为本项目主要负责人，负责该项目整体管理及统筹，其具体为临床前实体筛选、药效评价、毒理评估及临床试验批件申报等。

申请人自主研发新型BET抑制剂NHWD-870主要临床适应症为难治性复发的晚期癌症病人，这部分患者在临床上已经无药可用，研发此药物有望成为这部分患者最后医治的希望，具有重大临床应用价值和现实的社会效益。

讲授课程：

序号

课程名称

学期数

总学时数

选学总人数

1

生物技术技能培训（耶鲁大学开云全站中国有限公司）

2

48

34

2

组织病理实验技术培训（耶鲁大学开云全站中国有限公司）

4

96

15

3

皮肤病基础与临床研究设计

1

4

45

著作：

论文、著作名称

年份

排名

发表刊物名称

本人作用和主要贡献

教辅《轻松学习病理学》

2018

主编

湖北科学技术出版社 （ISBN：978-7-5352-9643-6）

负责本书整体的设计、排版、校对等工作，同时负责第7章节的撰写工作

教辅《临床病理生理学》

2022

主编

湖北科学技术出版社 （ISBN：978-7-5706-2212-2）

负责本书整体的设计、排版、校对等工作，同时负责10，18和20章节的撰写工作

专著《肿瘤标志物》

2022

编委

人民卫生出版社

（ISBN：9787117330817）

负责第3章-单细胞技术进展内容的编写工作

教材《临床研究伦理学》

未出版

编委

人民卫生出版社（书号：未出）

负责第5章-临床研究中人类遗传资源管理内容的编写工作

译著《ABC皮肤病》

2023

主译

湖南科学技术出版社（ISBN：978-7-5710-1869-6）

负责本书整体的设计、排版、校对及部分翻译工作

研究领域：

主要从事于肿瘤表观遗传学、癌症生物学、肿瘤免疫学及创新药物转化等方面的研究。最早系统阐述了肿瘤相关巨噬细胞主导肿瘤转移的作用机理，阐明KDM5B、CECR2和BET等表观遗传新靶点在肿瘤生长、转移中的功能及其肿瘤免疫调节机制；同时针对表观遗传新靶点BET开发了新一代小分子抑制剂NHWD-870，该项目现已完成临床Ⅰ期试验；另外，首次报道了表观遗传新靶点CECR2通过调控肿瘤微环境调节肿瘤转移新机制，为该靶点后期临床应用提供理论依据。

临床研究创新：

印明柱教授团队现自主在研的国家1.1类原创新药5项，其中已获批国家临床试验批件3项。针对表观遗传新靶点BET开发的新型BRD4抑制剂NHWD-870作为1.1类原创新药已经成功转化，现在已完成的临床I期试验中获得较高的安全性，同时也在淋巴瘤、肺鳞癌和中线（NUT）癌等适应症上观察到了较好疗效，现已开展临床II期试验。现阶段团队正在基于临床上市的高毒性JAK、PARP1、HER2抑制剂进行全新思路研发，已获得高选择性TYK2和JAK1，而不结合JAK2靶点，从而实现体内作用更精准，安全性更高。已获批国家1.1类原创新药临床试验批件1项，今年将开展临床I期试验。

发表文章：

（共发表SCI论文94篇，第一/通讯（含共同）44篇,Google学术H指数33）

2023年

  1. Huang L, Wang X, Pei S, Li X, Dong L, Bian X, Sun H, Jin L, Hou H, Shi W, Zhang X, Zhang L, Zhao S, Chen X, Yin M*. Single-cell profiling reveals sustained immune infiltration, surveillance, and tumor heterogeneity in infiltrative BCC. J Invest Dermatol. 2023, S0022-202X(23)02066-3. doi: 10.1016/j.jid.2023.04.020.

  2. Liu T, Fang ZY, Li X, Zhang LN, Cao DS*, Yin MZ*. Graph deep learning enabled spatial domains identification for spatial transcriptomics. Brief Bioinform. 2023 May 19, 24(3):bbad146. doi: 10.1093/bib/bbad146.

  3. Guo Y, Jin L, Dong L, Zhang M, Kuang Y, Chen X*, Zhu W*, Yin M*. NHWD-1062 ameliorates inflammation and proliferation by the RIPK1/NF-κB/TLR1 axis in Psoriatic Keratinocytes. BIOMED PHARMACOTHER. 2023 Jun, 162: 114638. doi: 10.1016/j.biopha.2023.114638.

  4. Hu R, Li Y, Guo Y, Li X, Du S, Liao M, Hou H, Sun H, Zhao S, Su J, Chen X*, Yin M*. BRD4 inhibitor suppresses melanoma metastasis via the SPINK6/EGFR-EphA2 pathway. Pharmacol Res. 2023 Jan, 187: 106609. doi: 10.1016/j.phrs.2022.106609.

  5. Zeng F, Li Y, Meng Y, Sun H, He Y, Yin M*, Chen X*, Deng G*. BET inhibitors synergize with sunitinib in melanoma through GDF15 suppression. Exp Mol Med. 2023 Feb, 55(2): 364-376. doi: 10.1038/s12276-023-00936-y.

  6. Li Z, Wu X, Chen S, Zhong J, Qiu X, Kpegah JKSK, Shi K, Can L, Zhang X, Yin M, Xie H, Su J, Zhou J. Identification of CRKL as an oncogenic biomarker for prognosis and immunotherapy in melanoma, and its potential molecular mechanism. Genomics. 2023, 115 (3): 110634. doi: 10.1016/j.ygeno.2023.110634.

  7. Hongyin Sun, Kui Deng, Xingchen Zhou, Dongsheng Cao, Yan Cheng, Xiang Chen, Mingzhu Yin*. A novel gene prognostic signature lymphocyte cytosolic protein 2 regulates melanoma progression by activating tumor-infiltrating CD8+ T-cells through the interferon regulatory factor 5 signaling pathway. Tumor Discovery 2023, 2(1), 318. https://doi.org/10.36922/td.318.

    2022年

  8. Zhang M, Liu ZZ, Aoshima K, Cai WL, Sun H, Xu T, Zhang Y, An Y, Chen JF, Chan LH, Aoshima A, Lang SM, Tang Z, Che X, Li Y, Rutter SJ, Bossuyt V, Chen X, Morrow JS, Pusztai L, Rimm DL, Yin M*, Yan Q*. CECR2 drives breast cancer metastasis by promoting NF-κB signaling and macrophage-mediated immune suppression. SCI TRANSL MED. 2022 Feb 2, 14 (630): eabf5473. doi: 10.1126/scitranslmed.abf5473.

  9. Du S, Zeng F, Sun H, Liu Y, Han P, Zhang B, Xue W, Deng G*, Yin M*, Cui B*. Prognostic and therapeutic significance of a novel ferroptosis related signature in colorectal cancer patients. BIOENGINEERED. 2022 Feb, 13 (2): 2498-2512. doi: 10.1080/21655979.2021.2017627.

  10. Deng G, Zeng F, He Y, Meng Y, Sun H, Su J, Zhao S, Cheng Y, Chen X*, Yin M*. EEF2K silencing inhibits tumour progression through repressing SPP1 and synergizes with BET inhibitors in melanoma. Clinical and Translational Medicine. 2022 Feb, 12(2): e722. doi: 10.1002/ctm2.722.

  11. Sun H, Huang B*, Cao J*, Yan Q*, Yin M*. Editorial: Epigenetic Regulation and Tumor Immunotherapy. Front Oncol. 2022 May 5, 12: 893157. doi: 10.3389/fonc.2022.893157.

  12. Chen X, Wang K, Jiang S, Sun H, Che X, Zhang M, He J, Wen Y, Liao M, Li X, Zhou X, Song J, Ren X, Yi W, Yang J, Chen X, Yin M*, Cheng Y*. eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma. J Immunother Cancer. 2022 Mar, 10(3): e004026. doi: 10.1136/jitc-2021-004026.

  13. Peng C, Jian X, Xie Y, Li L, Ouyang J, Tang L, Zhang X, Su J, Zhao S, Liu H, Yin M, Wu D, Wan M, Xie L, Chen X. Genomic alterations of dermatofibrosarcoma protuberans revealed by whole-genome sequencing. Br J Dermatol. 2022, 186(6): 997-1009. doi: 10.1111/bjd.20976.

  14. Jiang R, Xu J, Zhang Y, Liu J, Wang Y, Chen M*, Chen X*, Yin M*. Ligustrazine alleviates psoriasis-like inflammation through inhibiting TRAF6/c-JUN/NFκB signaling pathway in keratinocyte. Biomed Pharmacother. 2022 Jun, 150: 113010. doi: 10.1016/j.biopha.2022.113010.

  15. Farshidfar F, Rhrissorrakrai K, Levovitz C, Peng C, Knight J, Bacchiocchi A, Su J, Yin M, Sznol M, Ariyan S, Clune J, Olino K, Parida L, Nikolaus J, Zhang M, Zhao S, Wang Y, Huang G, Wan M, Li X, Cao J, Yan Q, Chen X, Newman AM, Halaban R. Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis. Nat Commun. 2022,13(1): 898. doi: 10.1038/s41467-022-28566-4.

  16. Fu X , Yin M*. Monocytes in tumor: from the sight of Single-cell analysis.  Tumor Discovery. 2022, 1 (1): 1-19.

  17. Yin M. Editor's foreword to the inaugural issue of Tumor Discovery. Tumor Discovery. 2022, 1 (1): 1-3.

  18. Zhang X, Guo Y, Xiao T, Li J, Guo A, Lei L, Jin C, Long Q, Su J, Yin M, Liu H, Chen C, Zhou Z, Zhu S, Tao J, Hu S, Chen X, Peng C. CD147 mediates epidermal malignant transformation through the RSK2/AP-1 pathway. J Exp Clin Cancer Re, 2022, 41(1): 246. doi: 10.1186/s13046-022-02427-w.

  19. Wang W, Liu X, Zhang Z, Yin M, Chen X, Zhao S, Wu L. Apigenin Induced Apoptosis by Downregulating Sulfiredoxin Expression in Cutaneous Squamous Cell Carcinoma. OXID MED CELL LONGEV. 2022, 2022: 8172866. doi: 10.1155/2022/8172866.

  20. Xiao Y, Jing D, Tang Z, Peng C, Yin M, Liu H, Chen X, Shen M. Serum lipids and risk of incident psoriasis: a prospective cohort study from the UK Biobank study and Mendelian randomization analysis. J Invest Dermatol, 2022, 142(12): 3192-3199.e12. doi: 10.1016/j.jid.2022.06.015.

  21. Zhang Y, Xia J, Zhang J, Mao J, Chen H, Lin H, Jiang P, He X, Xu X, Yin M*, Wang Z*. Validity of a Soft and Flexible 3D-Printed Nissen Fundoplication Model in Surgical Training. International Journal of Bioprinting, 2022 Mar 23, 8 (2): 546. doi: 10.18063/ijb.v8i2.546.

  22. Li X, Zhao S, Bian X, Zhang L, Lu L, Pei S, Dong L, Shi W, Huang L, Zhang X, Chen M, Chen X*, Yin M*. Signatures of EMT, immunosuppression, and inflammation in primary and recurrent human cutaneous squamous cell carcinoma at single-cell resolution. Theranostics, 2022 Oct 31, 12(17): 7532-7549. doi: 10.7150/thno.77528.

  23. Wu S, Li X, Shang L, Wu L, Li T, Li P, Ji Z, Hou J, Yin M*, Xu W*. The novel BRDT inhibitor NHWD870 shows potential as a male contraceptive in mice. Acta Biochim Biophys Sin (Shanghai). 2022, 54(12): 1789-1800. doi: 10.3724/abbs.2022135.

    2021年

  24. Pei S, Yuan X, Zhang Z, Yao R, Xie Y, Shen M, Li B*, Chen X*, Yin M*. Convalescent Plasma to Treat COVID-19: Clinical Experience and Efficacy. Aging (Albany NY). 2021 Mar 18, 13 (6): 7758-7766. doi: 10.18632/aging.202795.

  25. Zhu S, Guo Y, Zhang X, Liu H, Yin M, Chen X, Peng C. Pyruvate kinase M2 (PKM2) in cancer and cancer therapeutics. Cancer Lett. 2021, 503: 240-248. doi: 10.1016/j.canlet.2020.11.018.

  26. Vouga M, Favre G, Martinez-Perez O,......, Yin M, Haessig A, Ackermann S, Baud D, Panchaud A. Maternal outcomes and risk factors for COVID-19 severity among pregnant women. Sci Rep. 2021;11(1):13898. doi: 10.1038/s41598-021-92357-y.

  27. Lu Y, Xiao Y, Yin MZ, Zhou XC, Wu LS, Chen WQ, Luo Y, Kuang YH, Zhu W. Polyethylene Glycol Ointment Alleviates Psoriasis-Like Inflammation Through Down-Regulating the Function of Th17 Cells and MDSCs. Front Med (Lausanne). 2021, 7: 560579. doi: 10.3389/fmed.2020.560579.

  28. Dong L#, Pei S#, Ren Q, Fu S, Yu L, Chen H, Chen X*, Yin M*. Evaluation of vertical transmission of SARS-CoV-2 in utero: Nine pregnant women and their newborns. Placenta. 2021, 111: 91-96. doi: 10.1016/j.placenta.2021.06.007.

  29. Fu L, Yang ZY, Yang ZJ, Yin MZ, Lu AP, Chen X, Liu S, Hou TJ, Cao DS. QSAR-assisted-MMPA to expand chemical transformation space for lead optimization. Brief Bioinform. 2021, 22(5): bbaa374. doi: 10.1093/bib/bbaa374.

  30. Yang ZY, Dong J, Yang ZJ, Yin M, Jiang HL, Lu AP, Chen X, Hou TJ, Cao DS. ChemFLuo: a web-server for structure analysis and identification of fluorescent compounds. Brief Bioinform. 2021, 22(4): bbaa282. doi: 10.1093/bib/bbaa282.

  31. Guo Y, Shen M, Zhang X, Xiao Y, Zhao S, Yin M, Bu W, Wang Y, Chen X, Su J. Unemployment and Health-Related Quality of Life in Melanoma Patients During the COVID-19 Pandemic. Front Public Health. 2021, 9: 630620. doi: 10.3389/fpubh.2021.630620.

  32. Yang ZY, Yang ZJ, Zhao Y, Yin MZ, Lu AP, Chen X, Liu S, Hou TJ, Cao DS. PySmash: Python package and individual executable program for representative substructure generation and application. Brief Bioinform. 2021, 22(5): bbab017. doi: 10.1093/bib/bbab017.

  33. Hu R, Zhao S, Su J, Chen X*, Yin M*. Establishment of cultured primary acral melanoma cells and animal models for Chinese patients. Pigment Cell Melanoma Res. 2021 Nov, 34 (6): 1131-1137. doi: 10.1111/pcmr.12996.

  34. Xiong G, Wu Z, Yi J, Fu L, Yang Z, Hsieh C, Yin M, Zeng X, Wu C, Lu A, Chen X, Hou T, Cao D. ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Res. 2021, 49(W1): W5-W14. doi: 10.1093/nar/gkab255.

  35. Jiang Y, Wang G, Mu H, Ma X, Wang Z, Lv Y, Zhang T, Xu J, Wang J, Li Y, Han J, Yang M, Wang Z, Zeng K, Jin X, Xue S, Yin M, Sun W, Hua Y, Cai Z. Bromodomain Inhibition Attenuates the Progression and Sensitizes the Chemosensitivity of Osteosarcoma by Repressing GP130/STAT3 Signaling. Front Oncol. 2021, 11: 642134. doi: 10.3389/fonc.2021.642134.

  36. Liu N, Zhang J, Yin M, Liu H, Zhang X, Li J, Yan B, Guo Y, Zhou J, Tao J, Hu S, Chen X, Peng C. Inhibition of xCT suppresses the efficacy of anti-PD-1/L1 melanoma treatment through exosomal PD-L1-induced macrophage M2 polarization. Mol Ther. 2021, 29(7): 2321-2334. doi: 10.1016/j.ymthe.2021.03.013.

  37. Zhang SM, Cai WL, Liu X, Thakral D, Luo J, Chan LH, McGeary MK, Song E, Blenman KRM, Micevic G, Jessel S, Zhang Y, Yin M, Booth CJ, Jilaveanu LB, Damsky W, Sznol M, Kluger HM, Iwasaki A, Bosenberg MW, Yan Q. KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements. NATURE. 2021, 598 (7882): 682-687. doi: 10.1038/s41586-021-03994-2.

    2020年

  38. Hu R, Han C, Pei S, Yin M*, Chen X*. Procalcitonin Levels in COVID-19 Patients. Int J Antimicrob Agents. 2020 Aug, 56(2):106051. doi: 10.1016/j.ijantimicag.2020.106051.

  39. Jin L, Liu P, Yin M, Zhang M, Kuang Y, Zhu W. RIPK1: A rising star in inflammatory and neoplastic skin diseases. J Dermatol Sci. 2020, 99(3): 146-151. doi: 10.1016/j.jdermsci.2020.06.001.

  40. Yin M*, Guo Y, Hu R, Cai WL, Li Y, Pei S, Sun H, Peng C, Li J, Ye R, Yang Q, Wang N, Tao Y, Chen X, Yan Q. Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction. Nat Commun. 2020 Apr 14, 11(1): 1833. doi: 10.1038/s41467-020-15290-0.

  41. Liu N, Qi M, Li K, Zeng W, Li J, Yin M, Liu H, Chen X, Zhang J, Peng C. CD147 Regulates Melanoma Metastasis via the NFAT1-MMP-9 Pathway. Pigment Cell Melanoma Res. 2020, 33(5): 731-743. doi: 10.1111/pcmr.12886.

  42. Zeng F, Huang Y, Guo Y, Yin M, Chen X, Xiao L, Deng G. Association of inflammatory markers with the severity of COVID-19: A meta-analysis. Int J Infect Dis. 2020, 96: 467-474. doi: 10.1016/j.ijid.2020.05.055.

  43. Deng G, Zeng F*, Zhang L*, Chen H*, Chen X*, Yin M*. Characteristics of Pregnant COVID-19 Patients with Liver Injury. J Hepatol. 2020 Oct, 73(4): 989-991. doi: 10.1016/j.jhep.2020.06.022.

  44. Li Z#, Yin M#, Zhang H, Ni W, Pierce RW, Zhou HJ, Min W. BMX Represses Thrombin-PAR1-Mediated Endothelial Permeability and Vascular Leakage During Early Sepsis. Circ Res. 2020 Feb 14, 126(4): 471-485. doi: 10.1161/CIRCRESAHA.119.315769.

  45. Xue Y, Liu Y, Bian X, Zhang Y, Li Y*, Zhang Q*, Yin M*. miR-205-5p Inhibits Psoriasis-Associated Proliferation and Angiogenesis: Wnt/β-catenin and Mitogen-Activated Protein Kinase Signaling Pathway Are Involved. J Dermatol.2020, 47(8): 882-892. doi: 10.1111/1346-8138.15370.

  46. Chen XS, Wang KS, Guo W, Li LY, Yu P, Sun XY, Wang HY, Guan YD, Tao YG, Ding BN, Yin M, Ren XC, Zhang Y, Chen CS, Ye YC, Yang JM, Cheng Y. UCH-L1-mediated Down-regulation of Estrogen Receptor α Contributes to Insensitivity to Endocrine Therapy for Breast Cancer. Theranostics. 2020, 10(4): 1833-1848. doi: 10.7150/thno.39814.

  47. Pei S, Xue Y, Zhao S, Alexander N, Mohamad G, Chen X*, Yin M*. Occupational Skin Conditions on the Front Line: A Survey Among 484 Chinese Healthcare Professionals Caring for Covid-19 Patients. J Eur Acad Dermatol Venereol. 2020 Aug, 34(8): e354-e357. doi: 10.1111/jdv.16570.

  48. Li LY, Chen XS, Wang KS, Guan YD, Ren XC, Cao DS, Sun XY, Li AX, Tao YG, Zhang Y, Yin MZ, Wang XL, Wu MH, Yang JM, Cheng Y. RSK2 protects human breast cancer cells under endoplasmic reticulum stress through activating AMPKα2-mediated autophagy. Oncogene. 2020, 39(43): 6704-6718. doi: 10.1038/s41388-020-01447-0.

  49. Liao M, Zeng F, Li Y, Gao Q, Yin M, Deng G, Chen X. A novel predictive model incorporating immune-related gene signatures for overall survival in melanoma patients. Sci Rep. 2020, 10(1): 12462. doi: 10.1038/s41598-020-69330-2.

  50. Guo Y, Shen M, Zhang X, Xiao Y, Zhao S, Yin M, Bu W, Wang Y, Chen X, Su J. Association of Socioeconomic Changes due to the COVID-19 Pandemic With Health Outcomes in Patients With Skin Diseases: Cross-Sectional Survey Study. J Med Internet Res. 2020, 22(9): e22288. doi: 10.2196/22288.

  51. Deng G#, Zeng F#, Su J, Zhao S, Hu R, Zhu W, Hu S, Chen X*, Yin M*. BET inhibitor suppresses melanoma progression via the noncanonical NF-κB/SPP1 pathway. Theranostics. 2020 Sep 15, 10(25): 11428-11443. doi: 10.7150/thno.47432.

  52. Guan Y, Jiang S, Ye W, Ren X, Wang X, Zhang Y, Yin M, Wang K, Tao Y, Yang J, Cao D, Cheng Y. Combined treatment of mitoxantrone sensitizes breast cancer cells to rapalogs through blocking eEF-2K-mediated activation of Akt and autophagy. Cell Death Dis. 2020, 11(11): 948. doi: 10.1038/s41419-020-03153-x.

  53. Yang SQ, Ye Q, Ding JJ, Yin MZ, Lu AP, Chen X, Hou TJ, Cao DS. Current advances in ligand-based target prediction. WIREs Comput Mol Sci. 2020, 1-21. doi: 10.1002/wcms.1504.

  54. Jin L, Liu P, Yin M, Zhang M, Kuang Y, Zhu W. RIPK1: A rising star in inflammatory and neoplastic skin diseases. J Dermatol Sci. 2020, 99(3): 146-151. doi: 10.1016/j.jdermsci.2020.06.001.

  55. Deng G, Yin M, Chen X, Zeng F. Clinical determinants for fatality of 44,672 patients with COVID-19. Crit Care. 2020, 24(1): 179. doi: 10.1186/s13054-020-02902-w.

  56. Liu P, Huang Z, Yin M, Liu C, Chen X, Pan P, Kuang Y. Safety and Efficacy of Ixekizumab and Antiviral Treatment for Patients with COVID-19: A structured summary of a study protocol for a Pilot Randomized Controlled Trial. Trials. 2020, 21(1): 999. doi: 10.1186/s13063-020-04925-8.

  57. Panchaud A, Favre G, Pomar L, Vouga M, Aebi-Popp K, Baud D; COVI-Preg group (Mingzhu Yin). An international registry for emergent pathogens and pregnancy. Lancet. 2020, 395(10235): 1483-1484. doi: 10.1016/S0140-6736(20)30981-8.

  58. Ye Y, Kuang X, Xie Z, Liang L, Zhang Z, Zhang Y, Ma F, Gao Q, Chang R, Lee HH, Zhao S, Su J, Li H, Peng J, Chen H, Yin M, Peng C, Yang N, Wang J, Liu J, Liu H, Han L, Chen X. Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1. Genome Med. 2020, 12(1): 83. doi: 10.1186/s13073-020-00780-z.

    2019年

  59. Hu B, Hu H, Yin M*, Sun Z, Chen X, Li Y, Sun Z, Liu C, Li L, Qiu Y*. Sertad1 promotes prostate cancer progression through binding androgen receptor ligand binding domain. Int J Cancer. 2019,144(3): 558-568. doi: 10.1002/ijc.31877.

  60. Yin M, Zhou HJ, Lin C, Long L, Yang X, Zhang H, Taylor H, Min W*. CD34+ KLF4+ Stromal Stem Cells Contribute to Endometrial Regeneration and Repair. Cell Rep. 2019, 27(9): 2709-2724.e3. doi: 10.1016/j.celrep.2019.04.088.

    2018年

  61. Li J, Yin M, Song W, Cui F, Wang W, Wang S, Zhu H. B Subunit of Human Chorionic Gonadotropin Promotes Tumor Invasion and Predicts Poor Prognosis of Early-Stage Colorectal Cancer. Cell Physiol Biochem. 2018, 45(1): 237-249. doi: 10.1159/000486770.

  62. Long L, Yin M, Min W. 3D Co-culture System of Tumor-associated Macrophages and Ovarian Cancer Cells. Bio Protoc. 2018 Apr 20, 8(8): e2815. doi: 10.21769/BioProtoc.2815.

  63. Han Z, Hu H, Yin M, Li X, Li J, Liu L, Liu B. miR-145 is critical for modulation of vascular smooth muscle cell proliferation in human carotid artery stenosis. J BIOL REG HOMEOS AG. 2018 May-Jun, 32 (3): 506-516.

    2017年

  64. Li L, Wei X, Wu B, Xiao Y, Yin M*, Yang Q*. siRNA-mediated knockdown of ID1 disrupts Nanog- and Oct-4-mediated cancer stem cell-likeness and resistance to chemotherapy in gastric cancer cells. ONCOL LETT. 2017, 13 (5): 3014-3024. doi: 10.3892/ol.2017.5828.

  65. Zhang L, Fu Z, Li X, Tang H, Luo J, Zhang D, Zhuang Y, Han Z*, Yin M*. Transforming growth factor β-activated kinase 1 inhibitor suppresses the proliferation in triple-negative breast cancer through TGF-β/TGFR pathway. CHEM BIOL DRUG DES. 2017, 90 (3): 450-455. doi: 10.1111/cbdd.12965.

  66. Yang K, Xia B, Wang W, Cheng J, Yin M, Xie, H, Li, J, Ma, L, Yang, C, Li, A, Fan, X, Dhillon, HS, Hou, Y, Lou, G, Li, K. A Comprehensive Analysis of Metabolomics and Transcriptomics in Cervical Cancer. Sci Rep. 2017, 7: 43353. doi: 10.1038/srep43353.

  67. Tan S, Feng B, Yin M, Zhou HJ, Lou G, Ji W, Li Y, Min W. Stromal Senp1 promotes mouse early folliculogenesis by regulating BMP4 expression. Cell Biosci. 2017, 7: 36. doi: 10.1186/s13578-017-0163-5.

  68. Yin M, Zhou HJ, Zhang J, Lin C, Li H, Li X, Li Y, Zhang H, Breckenridge DG, Ji W, Min W. ASK1-dependent endothelial cell activation is critical in ovarian cancer growth and metastasis. JCI Insight. 2017, 2 (18): e91828. doi: 10.1172/jci.insight.91828.

    2016年

  69. Yin MZ#, Tan S#, Li X, Hou Y, Cao G, Li K, Kou J, Lou G. Identification of phosphatidylcholine and lysophosphatidylcholine as novel biomarkers for cervical cancers in a prospective cohort study. TUMOR BIOL. 2016, 37 (4): 5485-5492. doi: 10.1007/s13277-015-4164-x.

  70. Cui CY, Sima J, Yin M, Michel M, Kunisada M, Schlessinger D. Identification of potassium and chloride channels in eccrine sweat glands. J Dermatol Sci. 2016, 81(2): 129-131. doi: 10.1016/j.jdermsci.2015.11.001.

  71. Cao G, Ye X, Xu Y, Yin M, Chen H, Kou J, Yu B. YiQiFuMai powder injection ameliorates blood-brain barrier dysfunction and brain edema after focal cerebral ischemia-reperfusion injury in mice. Drug Des Devel Ther. 2016, 10: 315-325. doi: 10.2147/DDDT.S96818.

  72. Huang B#, Yin M#, Li X, Cao G, Qi J, Lou G, Sheng S, Kou J, Chen K, Yu B. Migration-inducing gene 7 promotes tumorigenesis and angiogenesis and independently predicts poor prognosis of epithelial ovarian cancer. Oncotarget. 2016, 7(19): 27552-27566. doi: 10.18632/oncotarget.8487.  

  73. Fan L, Yin M, Ke C, Ge T, Zhang G, Zhang W, Zhou X, Lou G, Li K. Use of Plasma Metabolomics to Identify Diagnostic Biomarkers for Early Stage Epithelial Ovarian Cancer. J Cancer. 2016, 7 (10): 1265-1272. doi: 10.7150/jca.15074.

  74. Zou S, Teixeira AM, Yin M, Xiang Y, Xavier-Ferrucio J, Zhang PX, Hwa J, Min W, Krause DS. Leukaemia-associated Rho guanine nucleotide exchange factor (LARG) plays an agonist specific role in platelet function through RhoA activation. Thromb Haemost. 2016,116(3): 506-516. doi: 10.1160/TH15-11-0848.

  75. Cao G, Jiang N, Hu Y, Zhang Y, Wang G, Yin M, Ma X, Zhou K, Qi J, Yu B, Kou J. Ruscogenin Attenuates Cerebral Ischemia-Induced Blood-Brain Barrier Dysfunction by Suppressing TXNIP/NLRP3 Inflammasome Activation and the MAPK Pathway. Int J Mol Sci. 2016, 17(9): 1418. doi: 10.3390/ijms17091418.

  76. Yin M#, Li X#, Tan S#, Zhou HJ, Ji W, Bellone S, Xu X, Zhang H, Santin AD, Lou G, Min W. Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer. J Clin Invest. 2016, 126(11): 4157-4173. doi: 10.1172/JCI87252.

    2015年

  77. Ye Y#, Yin M#, Huang B, Wang Y, Li X, Lou G. CLIC1 a novel biomarker of intraperitoneal metastasis in serous epithelial ovarian cancer. Tumour Biol. 2015, 36(6): 4175-4179. doi: 10.1007/s13277-015-3052-8.

  78. Ji W#, Li Y#, He Y#, Yin M#, Zhou HJ, Boggon TJ, Zhang H, Min W. AIP1 Expression in Tumor Niche Suppresses Tumor Progression and Metastasis. CANCER RES. 2015, 75 (17): 3492-3504. doi: 10.1158/0008-5472.CAN-15-0088.

    2014年

  79. Cui CY, Yin M, Sima J, Childress V, Michel M, Piao Y, Schlessinger D. Involvement of Wnt, Eda and Shh at defined stages of sweat gland development. Development. 2014, 141(19): 3752-60. doi: 10.1242/dev.109231.

  80. Hou Y#, Yin M#, Sun F, Zhang T, Zhou X, Li H, Zheng J, Chen X, Li C, Ning X, Lou G, Li K. A metabolomics approach for predicting the response to neoadjuvant chemotherapy in cervical cancer patients. Mol Biosyst. 2014, 10(8): 2126-33. doi: 10.1039/c4mb00054d.

  81. Ge T, Yin M, Yang M, Liu T, Lou G. MicroRNA-302b suppresses human epithelial ovarian cancer cell growth by targeting RUNX1. Cell Physiol Biochem. 2014, 34(6): 2209-2220. doi: 10.1159/000369664.

    2013年

  82. Zhang T, Wu X, Ke C, Yin M, Li Z, Fan L, Zhang W, Zhang H, Zhao F, Zhou X, Lou G, Li K. Identification of potential biomarkers for ovarian cancer by urinary metabolomic profiling. J Proteome Res. 2013, 12(1): 505-512. doi: 10.1021/pr3009572.

  83. Yin M#, Hou Y#, Zhang T, Cui C, Zhou X, Sun F, Li H, Li X, Zheng J, Chen X, Li C, Ning X, Li K, Lou G. Evaluation of chemotherapy response with serum squamous cell carcinoma antigen level in cervical cancer patients: a prospective cohort study. PLoS One. 2013, 8(1): e54969. doi: 10.1371/journal.pone.0054969.

    2012年

  84. Yin M, Lou C, Zhang W, Meng F, Zhang H, Ning X, Zhou R, Dong X, Lou G. LAPTM4B overexpression is a novel independent prognostic marker for metastatic ovarian tumors. Int J Gynecol Cancer. 2012 Jan;22(1):54-62. doi: 10.1097/IGC.0b013e318234f9ac.

  85. Zhang T, Wu X, Yin M, Fan L, Zhang H, Zhao F, Zhang W, Ke C, Zhang G, Hou Y, Zhou X, Lou G, Li K. Discrimination between malignant and benign ovarian tumors by plasma metabolomic profiling using ultra performance liquid chromatography/mass spectrometry. Clin Chim Acta. 2012 May 18;413(9-10):861-8. doi: 10.1016/j.cca.2012.01.026.

  86. Fan L, Zhang W, Yin M, Zhang T, Wu X, Zhang H, Sun M, Li Z, Hou Y, Zhou X, Lou G, Li K. Identification of metabolic biomarkers to diagnose epithelial ovarian cancer using a UPLC/QTOF/MS platform. Acta Oncol. 2012 Apr; 51(4): 473-9. doi: 10.3109/0284186X.2011.648338.

  87. Kang Y, Yin M, Jiang W, Zhang H, Xia B, Xue Y, Huang Y. Overexpression of LAPTM4B-35 is associated with poor prognosis in colorectal carcinoma. Am J Surg. 2012 Nov;204(5):677-83. doi: 10.1016/j.amjsurg.2012.02.003.

  88. Yin M, Zhang H, Li H, Li X, Liu Y, Chen X, Lou G, Li K. The toxicity and long-term efficacy of nedaplatin and paclitaxel treatment as neoadjuvant chemotherapy for locally advanced cervical cancer. J Surg Oncol. 2012 Feb;105(2):206-11. doi: 10.1002/jso.22052.

    2011年

  89. Meng F, Song H, Luo C, Yin M, Xu Y, Liu H, Zhou R, Lou G. Correlation of LAPTM4B polymorphisms with cervical carcinoma. Cancer. 2011 Jun 15;117(12):2652-8. doi: 10.1002/cncr.25833.

  90. Yin M, Li C, Li X, Lou G, Miao B, Liu X, Meng F, Zhang H, Chen X, Sun M, Ling Q, Zhou R. Over-expression of LAPTM4B is associated with poor prognosis and chemotherapy resistance in stages III and IV epithelial ovarian cancer. J Surg Oncol. 2011 Jul 1;104(1):29-36. doi: 10.1002/jso.21912.

  91. Yin M, Zhao F, Lou G, Zhang H, Sun M, Li C, Hou Y, Li X, Meng F, Chen X. The long-term efficacy of neoadjuvant chemotherapy followed by radical hysterectomy compared with radical surgery alone or concurrent chemoradiotherapy on locally advanced-stage cervical cancer. Int J Gynecol Cancer. 2011 Jan;21(1):92-9. doi: 10.1111/IGC.0b013e3181fe8b6e.

  92. Yin M, Xu Y, Lou G, Hou Y, Meng F, Zhang H, Li C, Zhou R. LAPTM4B overexpression is a novel predictor of epithelial ovarian carcinoma metastasis. Int J Cancer. 2011 Aug 1;129(3):629-35. doi: 10.1002/ijc.25689.

    2010年

  93. Meng F, Luo C, Hu Y, Yin M, Lin M, Lou G, Zhou R. Overexpression of LAPTM4B-35 in cervical carcinoma: a clinicopathologic study. Int J Gynecol Pathol. 2010 Nov;29(6):587-93. doi: 10.1097/PGP.0b013e3181e0898e.  

  94. Meng FL, Yin MZ, Song HT, Yang H, Lou G, Zhou RL. LAPTM4B-35 overexpression is an independent prognostic marker in endometrial carcinoma. Int J Gynecol Cancer. 2010 Jul;20(5):745-50. doi: 10.1111/IGC.0b013e3181e02f90.

    发表中文论文10篇

  95. 卞小慧,印明柱*. EDA在少汗性外胚层发育不良的发病机制及Fc-EDA的治疗作用[J].皮肤科学通报, 2020, 37(1): 5. DOI: CNKI:SUN:ZYXW.0.2020-01-008.

  96. 杨巧红,张新江,杜清,李琳琳,蓝华全,吕依扬,黄舒蕾,印明柱*,魏小勇*. 胃癌靶向治疗机制及 中西医药物治疗情况的研究进展[J].转化医学电子杂志, 2018, 5(9): 9. DOI: CNKI:SUN:ZHDZ.0.2018-09-008.

  97. 夏百荣,印明柱,葛婷婷,卢北燕*,娄阁. Hepsin在卵巢上皮癌组织中的表达及其与预后的关系[J].中国妇产科临床杂志, 2013. DOI: CNKI:SUN:FKLC.0.2013-02-017.

  98. 印明柱,娄阁*,孙喜文. 血清蛋白指纹图谱检测在卵巢癌中应用研究进展[J].实用肿瘤学杂志, 2013, 27(002): 177-180. DOI: 10.3969/j.issn.1002-3070.2013.02.019.

  99. 陈秀玮,王丹云,刘佳,印明柱,娄阁,高颖,康熙熊,张广美*. 白桦脂酸对HeLa细胞的抑制作用及其机制研究[J].中国癌症杂志, 2012, 22(4): 5. DOI: 10.3969/j.issn.1007-3639.2012.04.003.

  100. 印明柱,娄阁*,陈秀玮,顾泰华. 新辅助化疗后根治性手术与同步放化疗在局部晚期宫颈癌的远期疗效评价[J].实用肿瘤学杂志, 2011, 25(1): 6. DOI: 10.3969/j.issn.1002-3070.2011.01.012.

  101. 王丹云,刘佳,印明柱,李雪婷,娄阁,刘运铎,陈秀玮*. 白桦酯醇诱导宫颈癌HeLa细胞凋亡及作用机制的研究[J].肿瘤, 2012, 32(4): 5. DOI:10.3781/j.issn.1109-0721.2012.04.002.

  102. 印明柱,刘伟,娄阁,夏百荣. 孕产期合并Krukenberg瘤一例报道[J].实用肿瘤学杂志, 2011, 25(3): 2. DOI: 10.3969/j.issn.1002-3070.2011.03.015.

  103. 刘珺珺,印明柱,李聪,娄阁. 阿米福汀联合腹腔灌注化疗治疗难治性及复发性卵巢癌疗效观察[J].亚太传统医药, 2011, 7(10): 3. DOI: CNKI:SUN:YTCT.0.2011-10-051.

  104. 印明柱,娄阁.新基因LAPTM4B与肿瘤[J].国际肿瘤学杂志, 2011, 38(1): 3. DOI: 10.3760/cma.j.issn.1673-422X.2011.01.004.

     

     



微信新浪微博QQQQ空间豆瓣网百度贴吧
上一篇周舟：国家级人才
下一篇卞修武*：中国科学院员工